Department of Radiology and Clinical Neurosciences, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, T2N2T9, Canada.
Division of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Neuroradiology. 2021 Jan;63(1):117-123. doi: 10.1007/s00234-020-02509-6. Epub 2020 Aug 1.
Deciding about whether an unruptured intracranial aneurysm (UIA) should be treated or not is challenging because robust data on rupture risks, endovascular treatment complication rates, and treatment success rates are limited. We aimed to investigate how neurointerventionalists conceptually approach endovascular treatment decision-making in UIAs.
In a web-based international multidisciplinary case-based survey among neurointerventionalists, participants provided their demographics and UIA treatment-volumes, estimated 5-year rupture rates, endovascular treatment complication and success rates and gave their endovascular treatment decision for 15 pre-specified UIA case-scenarios. Differences in estimated 5-year rupture rates, endovascular treatment complication and success rates based on physician and hospital characteristics were evaluated with the Kruskal-Wallis test. Multivariable logistic regression analysis was used to derive adjusted effect size estimates for predictors of endovascular treatment decision.
Two hundred-thirty-three neurointerventionalists from 38 countries participated in the survey (median age 47 years [IQR: 41-55], 25/233 [10.7%] females). The ranges of estimates for 5-year rupture risks, endovascular treatment complication rates, and particularly endovascular treatment success rates were wide, especially for UIAs in the posterior circulation. Estimated 5-year rupture risks, endovascular treatment complication and success rates differed significantly based on personal and institutional endovascular UIA treatment volume, and all three estimates were significantly associated with physicians' endovascular treatment decision.
Although several predictors of endovascular treatment decision were identified, there seems to be a high degree of uncertainty when estimating rupture risks, treatment complications, and treatment success for endovascular UIA treatment. More data on the clinical course of UIAs with and without endovascular treatment is needed.
未破裂颅内动脉瘤(UIA)是否应进行治疗存在挑战,因为关于破裂风险、血管内治疗并发症发生率和治疗成功率的可靠数据有限。我们旨在研究神经介入医师如何从概念上处理 UIA 的血管内治疗决策。
在一项针对神经介入医师的基于网络的国际多学科基于病例的调查中,参与者提供了他们的人口统计学和 UIA 治疗量、估计的 5 年破裂率、血管内治疗并发症和成功率,并对 15 个预先指定的 UIA 病例情景给出了他们的血管内治疗决策。根据医生和医院特征评估估计的 5 年破裂率、血管内治疗并发症和成功率的差异,采用 Kruskal-Wallis 检验。使用多变量逻辑回归分析得出血管内治疗决策预测因素的调整后效应大小估计。
来自 38 个国家的 233 名神经介入医师参与了该调查(中位数年龄 47 岁[IQR:41-55],25/233[10.7%]为女性)。5 年破裂风险、血管内治疗并发症率,特别是血管内治疗成功率的估计范围很广,尤其是在后循环中的 UIA。估计的 5 年破裂风险、血管内治疗并发症和成功率根据个人和机构的血管内 UIA 治疗量有显著差异,所有这三个估计都与医生的血管内治疗决策显著相关。
尽管确定了一些血管内治疗决策的预测因素,但在估计血管内 UIA 治疗的破裂风险、治疗并发症和治疗成功率时似乎存在高度不确定性。需要更多关于有和没有血管内治疗的 UIA 临床病程的数据。